Telix Pharmaceuticals (TLX) Current Leases (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Current Leases for 3 consecutive years, with $5.5 million the latest figure, recorded in Q4 2025.

• Quarterly Current Leases rose 214.74% year-over-year to $5.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.5 million (up 214.74% YoY) and the FY2025 annual result came in at $5.5 million, up 258.86% from the prior year.
• Current Leases climbed to $5.5 million in Q4 2025 per TLX's latest filing, from $1.8 million in the prior quarter.
• Over the last five years, Current Leases for TLX reached as high as $5.5 million in Q4 2025 and fell as low as $420203.7 in Q4 2023.
• A 3-year average of $2.6 million and a median of $1.8 million in 2024 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2024 — Current Leases jumped 319.5% — and 2025, when it surged 214.74%.
• Year by year, Current Leases stood at $420203.7 in 2023, then soared by 319.5% to $1.8 million in 2024, then jumped by 214.74% to $5.5 million in 2025.
• According to Business Quant data, Current Leases over the past three periods registered $5.5 million, $1.8 million, and $420203.7 for Q4 2025, Q4 2024, and Q4 2023 respectively.